Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Multi-centered, randomized, open label clinical trial to study the safety and effectivity of hydroxychloroquine + azithromycin to treat COVID-19 symptoms in primary care patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maimónides Biomedical Research Institute of Córdoba
• Treatments: Azithromycin; Hydroxychloroquine

Criteria

Inclusion Criteria:

• Patients with positive semi-quantitative PCR and COVID19 symptoms (fever, cough, diarrhea, dyspnoea, loss of smell).

• Signed informed consent

Exclusion Criteria:

• Retinal degeneration.

• Congenital or acquired long QT syndrome.

• Advanced liver failure.

• Renal insufficiency (incompatible with creatinine clearance less than 50 mL /minute).

• Allergic to hydroxychloroquine or azithromycin.

• Serious interaction with the drugs used.

• Pregnant or breastfeeding.

• Men and women in fertile and sexually active periods, who do not accept a highly effective contraceptive method.

• Inability to follow study procedures.